Glutathione

Definition

Glutathione is a tripeptide of glutamate, cysteine, and glycine, the body's most abundant intracellular antioxidant; it is synthesized in every cell rather than obtained primarily from outside.

The injectable market sells it chiefly for skin tone and general wellness, uses that sit far from the molecule's textbook biochemistry.

Evidence

Systematic reviews of glutathione for skin outcomes find limited, short-term, and mixed evidence: a 2019 review reported some skin-tone effects in small trials with oral and topical use, and a 2025 review in melasma reached guarded conclusions about efficacy and durability ^{[1, 2]}. Evidence specifically for intravenous or intramuscular glutathione is thinner than for the oral forms the reviews mostly cover.

No glutathione product is FDA-approved for cosmetic indications, and the trials that exist are small enough that a confident claim in either direction outruns the data.

The route is where the record thins to nothing. Searched in August 2026, the pairing of glutathione with skin lightening, whitening, bleaching, hyperpigmentation, or melanogenesis returns 206 indexed papers, of which 7 carry the clinical-trial publication type and 4 the randomized-controlled-trial type; narrowing the same search to records that also name an intravenous, intramuscular, injected, or injectable route returns 12 papers and no clinical trial of any kind ^[6].

All 7 clinical trials were read rather than counted. Six test an oral, buccal, or topical preparation: an eight-week open-label single-arm study of a glutathione lozenge in 30 Filipino women reported a fall in melanin index ^[3], and a double-blind randomized study in 46 participants compared topical and oral glutathione against each route alone ^[4]. The seventh is an injectable, and it is not a trial of this question: it tested a four-ingredient hyaluronate complex containing vitamin C, tranexamic acid, and glutathione in 120 patients with periorbital hyperpigmentation, which is a combination product for under-eye pigment rather than glutathione alone for skin tone ^{[5, 6]}.

Safety is the thinner half of that record. A 2016 review found no study of intravenous glutathione for skin lightening and no study of its safety in long-term use for any indication; the intravenous trials in other conditions reported no or minimal adverse effects but lasted only a few doses ^[12]. A 2026 narrative review reached the same place a decade later, naming hepatotoxicity, hypersensitivity reactions and possible renal and endocrine effects as open safety concerns and judging the evidence too limited to justify routine cosmetic use ^[11].

Side effects

No controlled trial has characterized the safety of intravenous or intramuscular glutathione as it is sold for skin tone and wellness. A 2016 review found no study of intravenous glutathione for skin lightening and no study of its long-term safety for any indication; the short intravenous trials in other conditions reported no or minimal adverse effects ^[12]. A 2026 review lists hepatotoxicity, hypersensitivity reactions and possible renal and endocrine effects as unresolved concerns ^[11].

The best-documented harms come from contaminated ingredients rather than from the molecule. In 2019 the FDA reported nausea, vomiting, lightheadedness, chills, body aches and fever in patients given compounded intravenous glutathione made from a dietary-supplement powder, with two patients taken to hospital, and found excessive bacterial endotoxin in that powder ^[10]. More recently it reported at least 30 patients with fever, chills, pain, dizziness, signs of shock and sepsis-like symptoms, some hospitalized, after intravenous glutathione compounded from one lot of dietary supplement grade material ^[9].

Case reports show what can happen without establishing how often. A 2025 report describes shock, very high fever, liver injury and abnormal clotting within an hour of an unregulated glutathione infusion for skin lightening; the patient recovered, and the authors suspected endotoxin contamination ^[13]. The oral and topical forms that most skin trials tested are different exposures, and their results do not describe an infusion ^{[1, 2]}.

Educational summary of the cited sources, not medical advice; a prescriber weighs these risks against a person’s own history.

Lawful access

Glutathione is listed in Category 1 of the FDA's interim 503A bulks list; licensed pharmacies may compound it with a valid prescription while review continues.

The injectable skin-whitening trade sits outside that route entirely, and the federal record of it is dated. A consent decree of permanent injunction was entered in the United States District Court for the District of New Jersey on September 26, 2017 in United States v. Flawless Beauty LLC, a case the FDA still cites by number in its own correspondence ^[7]; under that decree the company announced on January 18, 2018 a recall of nineteen products, and the announcement the FDA republished states that all of the glutathione products were sold in multi-vial whitening kits, alone or with ampules of vitamin C and sterile water ^[8]. That action is a dated public record and nothing more; it says nothing about any other seller.

The FDA's most recent warnings concern the ingredient rather than the indication. In June 2019 the agency reported adverse events in patients given intravenous glutathione compounded from a powder labeled as a dietary supplement, and its laboratory found excessive bacterial endotoxin in samples of that powder ^[10]. On August 27, 2026 it reported at least 30 patients with adverse events after intravenous glutathione compounded by different pharmacies from a single lot of dietary supplement grade glutathione, and reminded compounders not to use dietary supplement grade ingredients in injectable drugs ^[9]. A single case report from 2025 describes systemic inflammatory response syndrome within an hour of an unregulated glutathione infusion given for skin lightening ^[13].

Related molecules

Glutathione shares its Category 1 posture with NAD+, and both appear on the compoundable page; the mitochondrial group is the nearest class comparison in how these compounds are marketed. Vasoactive intestinal peptide holds the same Category 1 position and is the clearest case of it, having no approved product to be compared against.

Elsewhere in this index